Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Risankizumab versus apremilast in adults with moderate plaque psoriasis
2020-005512-21Phase 3Completed
- Sponsor
- AbbVie Inc.
- Start
- May 2021
- Modality
- Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial in plaque psoriasis comparing Risankizumab with Apremilast (2 arms). Primary endpoints: PASI 90 at Week 16 and sPGA 0 or 1 with at least 2-grade improvement at Week 16. Started May 2021; status: completed.
02
Drugs
risankizumabapremilast
03
Conditions
plaque psoriasis
Beyond the preview
Go deeper on 2020-005512-21.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-005512-21.